Enzyme-mediated protein haptenation of dapsone and sulfamethoxazole in human keratinocytes: I. Expression and role of cytochromes P450

Journal of Pharmacology and Experimental Therapeutics

Volumn 319, Issue 1, 2006, Pages 488-496

  Vyas, Piyush M ^a   Roychowdhury, Sanjoy ^a   Khan, Farah D ^a   Prisinzano, Thomas E ^a   Lamba, Jatinder ^b   Schuetz, Erin G ^b   Blaisdell, Joyce ^c   Goldstein, Joyce A ^c   Munson, Kimber L ^d   Hines, Ronald N ^d   Svensson, Craig K ^a,e  

^a UNIVERSITY OF IOWA   (United States)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^c NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^d CHILDREN S HOSPITAL OF WISCONSIN   (United States)

^e PURDUE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 DICHLOROETHYLENE; AMINOBENZOTRIAZOLE; CYTOCHROME P450; CYTOCHROME P450 2C9; CYTOCHROME P450 2E1; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; CYTOCHROME P450 INHIBITOR; DAPSONE; INDOMETACIN; PROSTAGLANDIN SYNTHASE INHIBITOR; SULFAMETHOXAZOLE; UNCLASSIFIED DRUG;

ACETYLATION; ARTICLE; CELLULAR DISTRIBUTION; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; ENZYME ASSAY; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LOCALIZATION; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; KERATINOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN HAPTENATION; PROTEIN METABOLISM; RNA ANALYSIS; XENOBIOTIC METABOLISM;

ACETYLATION; CELLS, CULTURED; CYTOCHROME P-450 ENZYME SYSTEM; DAPSONE; HAPTENS; HUMANS; KERATINOCYTES; SULFAMETHOXAZOLE;

EID: 33749009323     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.106.105858     Document Type: Article

References (35)

1. Balani SK, Zhu T, Yang TJ, Liu Z, He B, and Lee FW (2002) Effective dosing regimen of 1-aminobenzotriazole for inhibition of antipyrine clearance in rats, dogs, and monkeys. Drug Metab Dispos 30:1059-1062.
2. Baron JM, Holler D, Schiffer R, Frankenberg S, Neis MMH, and Jugert FK (2001) Expression of multiple cytochrome p450 enzymes and multidrug. J Investig Dermatol 116:541-548.
3. Beaune P, Kremers P, Letawe-Goujon F, and Gielen JE (1985) Monoclonal antibodies against human liver cytochrome P-450. Biochem Pharmacol 34:3547-3552.
4. Berg PA and Daniel PT (1987) Co-trimoxazole-induced liver injury: an analysis of cases with hypersensitivity-like reactions. Infection 15:S259-S263.
5. Cribb AE, Lee BL, Trepanier LA, and Spielberg SP (1996a) Adverse reactions to sulphonamide and sulphonamide-trimethoprim antimicrobials: clinical syndromes and pathogenesis. Adv Drug React Toxicol Rev 15:9-50.
6. Cribb AE, Miller M, Tesoro A, and Spielberg SP (1990) Peroxidase-dependent oxidation of sulfonamides by monocytes and neutrophils from humans and dogs. Mol Pharmacol 38:744-751.
7. Cribb AE, Nuss CE, Alberts DW, Lamphere DB, Grant DM, Grossman SJ, and Spielberg SP (1996b) Covalent binding of sulfamethoxazole reactive metabolites to human and rat liver subcellular fractions assessed by immunochemical detection. Chem Res Toxicol 9:500-507.
8. Cribb AE, Spielberg SP, and Griffin GP (1995) N4-hydroxylation of sulfamethoxazole by cytochrome P450 of the cytochrome P4502C subfamily and reduction of sulfamethoxazole hydroxylamine in human and rat hepatic microsomes. Drug Metab Dispos 23:406-414.
9. Du L, Neis MM, Ladd PA, Lanza DL, Yost GS, and Keeney DS (2006) Effects of the differentiated keratinocyte phenotype on expression levels of CYP1-4 family genes in human skin cells. Toxicol Appl Pharmacol 213:135-144.
10. Dujovne D, Chan C, and Zimmerman H (1967) Sulfonamide hepatic injury. N Engl J Med 377:785-788.
11. Gill HJ, Tija J, Kitteringham NR, Pirmohamed M, Back DJ, and Park BK (1999) The effect of genetic polymorphism in CYP2C9 on sulphamethoxazole N-hydroxylation. Pharmacogenetics 9:43-53.
12. Goebel C, Vogel C, Wulferink M, Mittmann S, Sachs B, Schraa S, Abel J, Degen G, Uetrecht J, and Gleichmann E (1999) Procainamide, a drug causing lupus, induces prostaglandin H synthase-2 and formation of T cell-sensitizing drug metabolites in mouse macrophages. Chem Res Toxicol 12:488-500.
13. Goldie SJ, Kaplan JE, Losina E, Weinstein MC, Paltiel AD, Seage GR, Craven DE, Kimmel AD, Zhang H, Cohen CJ, et al. (2002) Prophylaxis for human immunodeficiency virus-related Pneumocystis carinii pneumonia: using simulation modeling to inform clinical guidelines. Arch Intern Med 162:921-928.
14. Goldstein JA, Faletto MB, Romkes-Sparkes M, Sullivan T, Kitareewan S, Raucy JL, Lasker JM, and Ghanayem BI (1994) Evidence that CYP2C19 is the major (S)-mephenytoin 4′-hydroxylase in humans. Biochemistry 33:1743-1752.
15. Haufroid V, Toubeau F, Clippe A, Buysschaert M, Gala JL, and Lison D (2001) Real-time quantification of cytochrome P4502E1 mRNA in human peripheral blood lymphocytes by reverse transcription-PCR: method and practical application. Clin Chem 47:1126-1129.
16. Hughes WT (1987) Treatment and prophylaxis for Pneumocystis carinii pneumonia. Parasitol Today 3:332-335.
17. Janmohamed A, Dolphin CT, Phillips IR, and Shephard EA (2001) Quantification and cellular localization of expression in human skin of genes encoding flavin-containing monooxygenases and cytochromes P450. Biochem Pharmacol 62:777-786.
18. Kanekura T, Laulederkind SJ, Kirtikara K, Goorha S, and Ballou LR (1998) Cholecalciferol induces prostaglandin E2 biosynthesis and transglutaminase activity in human keratinocytes. J Investig Dermatol 111:634-639.
19. Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J, Watkins PB, Daly A, Wrighton SA, Hall SD, et al. (2001) Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 27:383-391.
20. Liu Y and Levy GN (1998) Activation of heterocyclic amines by combinations of prostaglandin H synthase-1 and -2 with N-acetyltransferase 1 and 2. Cancer Lett 133:115-123.
21. Mitra AK, Thummel KE, Kalhorn TF, Kharasch ED, Unadkat JD, and Slattery JT (1995) Metabolism of dapsone to its hydroxylamine by CYP2E1 in vitro and in vivo. Clin Pharmacol Ther 58:556-566.
22. Reilly TP and Ju C (2002) Mechanistic perspectives on sulfonamide-induced cutaneous drug reactions. Curr Opin Allergy Clin Immunol 2:307-315.
23. Reilly TP, Lash LH, Doll MA, Hein DW, Woster PM, and Svensson CK (2000) A role for bioactivation and covalent binding within epidermal keratinocytes in sulfonamide-induced cutaneous drug reactions. J Investig Dermatol 114:1164-1173.
24. Rieder MJ, Uetrecht J, Shear NH, Cannon M, Miller M, and Spielberg SP (1989) Diagnosis of sulfonamide hypersensitivity reactions by in-vitro "rechallenge" with hydroxylamine metabolites. Ann Intern Med 110:286-289.
25. Roychowdhury S, Vyas PM, Reilly TP, Gaspari AA, and Svensson CK (2005) Characterization of the formation and localization of sulfamethoxazole and dapsone-associated drug-protein adducts in human epidermal keratinocytes. J Pharmacol Exp Ther 314:43-52.
26. Rys-Sikora KE, Konger RL, Schoggins JW, Malaviya R, and Pentland AP (2000) Coordinate expression of secretory phospholipase A2 and cyclooxygenase-2 in activated human keratinocytes. Am J Physiol 278:C822-C833.
27. Saeki M, Saito Y, Nagano M, Teshima R, Ozawa S, and Sawada J (2002) mRNA expression of multiple cytochrome P450 isozymes in four types of cultured skin cells. Int Arch Allergy Immunol 127:333-336.
28. Svensson CK (2003) Do arylhydroxylamine metabolites mediate the idiosyncratic reactions associated with sulfonamides and sulfones? Chem Res Toxicol 16:1034-1043.
29. Svensson CK, Cowen EW, and Gaspari AA (2001) Cutaneous drug reactions. Pharmacol Rev 53:357-379.
30. Uetrecht JP (1990) Drug metabolism by leukocytes and its role in drug-induced lupus and other idiosyncratic drug reactions. Crit Rev Toxicol 20:213-235.
31. Vyas PM, Roychowdhury S, and Svensson CK (2006) Role of human cyclooxygenase-2 in the bioactivation of dapsone and sulfemethoxazole. Drug Metab Dispos 34:16-18.
32. Vyas PM, Roychowdhury S, Woster PM, and Svensson CK (2005) Reactive oxygen species generation and its role in the differential cytotoxicity of the arylhydroxylamine metabolites of sulfamethoxazole and dapsone in normal human epidermal keratinocytes. Biochem Pharmacol 70:275-286.
33. Winter HR, Wang Y, and Unadkat JD (2000) CYP 2C8/9 mediate dapsone N-hydroxylation at clinical concentrations of dapsone. Drug Metab Dispos 28:865-868.
34. Wurster W, Nemes R, Lamba J, Schuetz EG, Blaisdell J, Goldstein JA, Reilly TP, and Svensson CK (2004) Bioactivation of sulfamethoxazole (SMX) and dapsone (DDS) in normal human epidermal keratinocytes (NHEK) results in the formation of drug-protein adducts. Allergologie 4:169.
35. Yengi LG, Xiang Q, Pan J, Scatina J, Kao J, Ball SE, Fruncillo R, Ferron G, and Wolf CR (2003) Quantitation of cytochrome P450 mRNA levels in human skin. Anal Biochem 316:103-110.